Bristol-Myers Squibb has made significant strides in the biotech space. A key move includes the acquisition of cell therapy biotech
Orbital for $1.5 billion, expanding and diversifying their cell therapy portfolio. This was followed by insitro extending its research collaboration with the company, with a focus on
Artificial Intelligence (AI). Other notable actions include its plan to sell psoriasis drug at a significant discount to US patients and the divestment of a 60% stake in their
China joint venture amid strategic realignment. Furthermore, ALS collaboration with Insitro and a promising phase I trial result underscore BMY's commitment to innovation. Importantly, the company's stock appears undervalued and the acquisition of Orbital therapeutics shows potential for considerable return.
BMS-986446, BMY's Alzheimer's drug, granted FDA fast track status, signifies potential growth. Lastly, BMY's restructuring program is expected to boost its earnings growth, marking an essential step for its prosperity going forward.
Bristol-Myers Squibb News Analytics from Mon, 03 Feb 2025 08:00:00 GMT to Sat, 18 Oct 2025 20:22:08 GMT -
Rating 8
- Innovation 7
- Information 6
- Rumor -2
